Safety and Efficacy of Insulin NPH Compared to a New Insulin Formulation in Subjects With Type 2 Diabetes

Inclusion Criteria: * Type 2 diabetes for at least 12 months * Current NPH treatment for at least 3 months - alone or as the only insulin in combination with OADs * Body Mass Index (BMI) less than or equal to 40 kg/m2 * HbA1c less than or equal to 9.5% * FPG less than or equal to 12 mmol/L Exclusion Criteria: * Treatment with Glucagon-like peptide 1 mimetics or dipeptityl peptidase IV inhibitors * Treatment with more than 1 IU/kg NPH insulin daily * Known hypoglycaemia unawareness or recurrent major hypoglycaemia, as judged by the Investigator * Known or suspected allergy to trial products or related products * Receipt of any investigational drug within one month prior to this trial * Any other condition that the Investigator feels would interfere with trial participation or evaluation of results, e.g. shiftworkers